By RACHAEL LEVY and MARISA TAYLOR
Musk has said his brain implant company, Neuralink, will make the paralyzed walk, the blind see and eventually turn people into cyborgs. But the firm still struggles to secure clinical-trial approval for the relatively modest goal of helping disabled people type.
On at least four occasions since 2019, Elon Musk has predicted that his medical device company, Neuralink, would soon start human trials of a revolutionary brain implant to treat intractable conditions such as paralysis and blindness.
Yet the company, founded in 2016, didn’t seek permission from the U.S. Food and Drug Administration (FDA) until early 2022 – and the agency rejected the application, seven current and former employees told Reuters.
The rejection has not been previously reported. In explaining the decision to Neuralink, the agency outlined dozens of issues the company must address before human testing, a critical milestone on the path to final product approval, the staffers said. The agency’s major safety concerns involved the device’s lithium battery; the potential for the implant’s tiny wires to migrate to other areas of the brain; and questions over whether and how the device can be removed without damaging brain tissue, the employees said.
Home | Caravan to Midnight (zutalk.com)
We need your help to keep Caravan to Midnight going,
please consider donating to help keep independent media independent.